We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate in the Treatment of Patients With COPD

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00215436
First Posted: September 22, 2005
Last Update Posted: November 10, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Dey
September 13, 2005
September 22, 2005
November 10, 2010
March 2005
September 2005   (Final data collection date for primary outcome measure)
Measure of lung function
Same as current
Complete list of historical versions of study NCT00215436 on ClinicalTrials.gov Archive Site
  • Change in lung function, as well as vital signs
  • Physical Exam results, Adverse event reporting, etc
Same as current
Not Provided
Not Provided
 
A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate in the Treatment of Patients With COPD
A 12-week Double-Blind, Parallel-Group, Placebo- and Active- Controlled Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate Inhalation Solution 20 Mcg in the Treatment of Patients With Chronic Obstructive Pulmonary Disease
The purpose of this study is to determine the safety and efficacy of the investigational drug in comparison with a placebo.
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
COPD
Drug: Formoterol Fumarate
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
345
September 2006
September 2005   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Medical diagnosis of COPD
  • Current or prior history of cigarette smoking

Exclusion Criteria:

  • Medical diagnosis of asthma
  • Chest X-ray diagnostic of significant disease other than COPD
  • Significant condition or disease other than COPD
Sexes Eligible for Study: All
40 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00215436
201-065
Not Provided
Not Provided
Not Provided
Director Clinical Affairs, Dey L.P.
Dey
Not Provided
Not Provided
Dey
April 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP